Circadian Rhythm Modulation in Type 2 Diabetes: A New Frontier in Chronotherapy

Background: Type 2 diabetes mellitus (T2DM) is a growing global health concern, driven in part by modern lifestyle changes and technological influences. The circadian rhythm–a biological clock regulated by factors such as light, sleep, hormones, and metabolism–plays a crucial role in maintaining glucose homeostasis and coordinating meal timing. When disrupted, it contributes to the development of metabolic disorders, including cardiovascular disease, neurological dysfunction, immune dysregulation, cancer, and poor sleep quality.

Objective: To explore the potential of circadian-based therapies–both lifestyle and pharmacological–as emerging treatment strategies for managing T2DM.

 Materials and Methods: A comprehensive literature review was conducted using the PubMed, Google Scholar, Web of Science, Scopus, and Cochrane databases. Only recent English-language peer-reviewed studies on non-pharmacological approaches (e.g., exercise, time-restricted eating, light therapy) and pharmacological agents (e.g., melatonin, berberine, orexin modulators, and clock-targeting compounds like REV-ERB and CRY agonists) were included.

Results: Circadian disruption has been shown to impair insulin sensitivity and glucose regulation. Interventions that restore circadian alignment–such as light therapy and meal timing–improve metabolic outcomes. Certain drugs, including melatonin and berberine, also exhibit potential by modulating clock gene activity and enhancing glycemic control.

Conclusion: Targeting the circadian system through lifestyle adjustments and chronopharmacology offers a promising approach to managing T2DM. Further studies are needed to clarify mechanisms, personalize treatment based on individual circadian patterns, and assess long-term effectiveness.

1. Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes – Global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107-111. doi: 10.2991/jegh.k.191028.001

2. Westman EC. Type 2 diabetes mellitus: A pathophysiologic perspective. Front Nutr. 2021;8:707371. doi: 10.3389/fnut.2021.707371

3. Saigal N, Baboota S, Ahuja A, Ali J. Site specific chronotherapeutic drug delivery systems: A patent review. Recent Pat Drug Deliv Formul. 2009;3(1):64-70. doi: 10.2174/187221109787158328

4. Paul S, Hanna L, Harding C, et al. Output from VIP cells of the mammalian central clock regulates daily physiological rhythms. Nat Commun. 2020;11(1):1453. doi: 10.1038/s41467-020-15277-x

5. Koronowski KB, Sassone-Corsi P. Communicating clocks shape circadian homeostasis. Science. 2021;371(6530):eabd0951. doi: 10.1126/science.abd0951

6. Gale JE, Cox HI, Qian J, Block GD, Colwell CS, Matveyenko AV. Disruption of circadian rhythms accelerates development of diabetes through pancreatic β-cell loss and dysfunction. J Biol Rhythms. 2011;26(5):423-433. doi: 10.1177/0748730411416341

7. Wolk R, Somers VK. Sleep and the metabolic syndrome. Exp Physiol. 2007;92(1):67-78. doi: 10.1113/expphysiol.2006.033787

8. Mohawk JA, Green CB, Takahashi JS. Central and peripheral circadian clocks in mammals. Annu Rev Neurosci. 2012;35:445-462. doi: 10.1146/annurev-neuro-060909-153128

9. Segers A, Depoortere I. Circadian clocks in the digestive system. Nat Rev Gastroenterol Hepatol. 2021;18(4):239-251. doi: 10.1038/s41575-020-00369-4

10. Paul S, Hanna L, Harding C, et al. Output from VIP cells of the mammalian central clock regulates daily physiological rhythms. Nat Commun. 2020;11(1):1453. doi: 10.1038/s41467-020-15277-x

11. Bass J, Takahashi JS. Circadian integration of metabolism and energetics. Science. 2010;330(6009):1349-1354. doi: 10.1126/science.1195027

12. Woodie LN, Oral KT, Krusen BM, Lazar MA. The circadian regulation of nutrient metabolism in diet-induced obesity and metabolic disease. Nutrients. 2022;14(15):3136. doi: 10.3390/nu14153136

13. Chan K, Wong FS, Pearson JA. Circadian rhythms and pancreas physiology: A review. Front Endocrinol (Lausanne). 2022;13:920261. doi: 10.3389/fendo.2022.920261

14. Li JX, Cummins CL. Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat Rev Endocrinol. 2022;18(9):540-557. doi: 10.1038/s41574-022-00683-6

15. Zhao M, Jung Y, Jiang Z, Svensson KJ. Regulation of energy metabolism by receptor tyrosine kinase ligands. Front Physiol. 2020;11:354. doi: 10.3389/fphys.2020.00354

16. Deacon CF. Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors. Peptides. 2020;125:170196. doi: 10.1016/j.peptides.2019.170196

17. Lamia KA, Storch KF, Weitz CJ. Physiological significance of a peripheral tissue circadian clock. Proc Natl Acad Sci USA. 2008;105(39):15172-15177. doi: 10.1073/pnas.0806717105

18. Comtet H, Geoffroy PA, Kobayashi Frisk M, et al. Light therapy with boxes or glasses to counteract effects of acute sleep deprivation. Sci Rep. 2019;9(1):18073. doi: 10.1038/s41598-019-54311-x

19. Powner MB, Jeffery G. Light stimulation of mitochondria reduces blood glucose levels. J Biophotonics. 2024;17(5):e202300521. doi: 10.1002/jbio.202300521

20. Ferraresi C, Parizotto NA, Pires de Sousa MV, et al. Light-emitting diode therapy in exercise-trained mice increases muscle performance, cytochrome c oxidase activity, ATP and cell proliferation. J Biophotonics. 2015;8(9):740-754. doi: 10.1002/jbio.201400087

21. Harris C, Czaja K. Can circadian eating pattern adjustments reduce risk or prevent development of T2D? Nutrients. 2023;15(7):1762. doi: 10.3390/nu15071762

22. Guasch-Ferré M, Merino J, Sun Q, Fitó M, Salas-Salvadó J. Dietary polyphenols, Mediterranean diet, prediabetes, and type 2 diabetes: A narrative review of the evidence. Oxid Med Cell Longev. 2017;2017:6723931. doi: 10.1155/2017/6723931

23. Henry CJ, Kaur B, Quek RYC. Chrononutrition in the management of diabetes. Nutr Diabetes. 2020;10(1):6. doi: 10.1038/s41387-020-0109-6

24. Syeda USA, Battillo D, Visaria A, Malin SK. The importance of exercise for glycemic control in type 2 diabetes. Am J Med Open. 2023;9(8):100031. doi: 10.1016/j.ajmo.2023.100031

25. Heden TD, Kanaley JA. Syncing exercise with meals and circadian clocks. Exerc Sport Sci Rev. 2019;47(1):22-28. doi: 10.1249/JES.0000000000000172

26. Erickson ML, Zhang H, Mey JT, Kirwan JP. Exercise training impacts skeletal muscle clock machinery in prediabetes. Med Sci Sports Exerc. 2020;52(10):2078-2085. doi: 10.1249/MSS.0000000000002349

27. Chinoy ED, Harris MP, Kim MJ, Wang W, Duffy JF. Scheduled evening sleep and enhanced lighting improve adaptation to night shift work in older adults. Occup Environ Med. 2016;73(12):869-876. doi: 10.1136/oemed-2016-103712

28. Garde AH, Begtrup L, Bjorvatn B, et al. How to schedule night shift work in order to reduce health and safety risks. Scand J Work Environ Health. 2020;46(6):557-569. doi: 10.5271/sjweh.3920

29. Saini A, Gupta P. Chronotherapeutic agents: An overview. Indian Res J Pharm Sci. 2017;4(3):1144-1152. doi: 10.21276/irjps.2017.4.3.8

30. Fauler G, Abletshauser C, Erwa W, Löser R, Witschital K, März W. Time-of-intake (morning versus evening) of extended-release fluvastatin in hyperlipemic patients is without influence on the pharmacodynamics (mevalonic acid excretion) and pharmacokinetics. Int J Clin Pharmacol Ther. 2007;45(6):328-334. doi: 10.5414/cpp45328

31. Patel R, Parmar N, Pramanik Palit S, Rathwa N, Ramachandran AV, Begum R. Diabetes mellitus and melatonin: Where are we? Biochimie. 2022;202:2-14. doi: 10.1016/j.biochi.2022.07.013

32. Thomas AP, Hoang J, Vongbunyong K, Nguyen A, Rakshit K, Matveyenko AV. Administration of melatonin and metformin prevents deleterious effects of circadian disruption and obesity in male rats. Endocrinology. 2016;157(12):4720-4731. doi: 10.1210/en.2016-1309

33. Cai XJ, Evans ML, Lister CA, et al. Hypoglycemia activates orexin neurons and selectively increases hypothalamic orexin-B levels: Responses inhibited by feeding and possibly mediated by the nucleus of the solitary tract. Diabetes. 2001;50(1):105-512. doi: 10.2337/diabetes.50.1.105

34. Yoshikawa F, Shigiyama F, Ando Y, et al. Chronotherapeutic efficacy of suvorexant on sleep quality and metabolic parameters in patients with type 2 diabetes and insomnia. Diabetes Res Clin Pract. 2020;169:108412. doi: 10.1016/j.diabres.2020.108412

35. Yin J, Ye J, Jia W. Effects and mechanisms of berberine in diabetes treatment. Acta Pharm Sin B. 2012;2(4):327-334. doi: 10.1016/j.apsb.2012.06.003

36. Zhou Z, Lin Y, Gao L, Yang Z, Wang S, Wu B. Circadian pharmacological effects of berberine on chronic colitis in mice: Role of the clock component Rev-erbα. Biochem Pharmacol. 2020;172:113773. doi: 10.1016/j.bcp.2019.113773

37. Chambers CS, Holečková V, Petrásková L, et al. The silymarin composition… and why does it matter??? Food Res Int. 2017;100(Pt 3):339-353. doi: 10.1016/j.foodres.2017.07.017

38. Yung JHM, Giacca A. Role of c-Jun N-terminal kinase (JNK) in obesity and type 2 diabetes. Cells. 2020;9(3):706. doi: 10.3390/cells9030706

39. Rafieian-Kopaie M, Nasri H. Silymarin and diabetic nephropathy. J Renal Inj Prev. 2012;1(1):3-5. doi: 10.12861/jrip.2012.02

40. Holt RIG, Barnett AH, Bailey CJ. Bromocriptine: Old drug, new formulation and new indication. Diabetes Obes Metab. 2010;12(12):1048-1057. doi: 10.1111/j.1463-1326.2010.01304.x

41. Raskin P, Cincotta AH. Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: Developmental basis and therapeutic profile summary. Expert Rev Endocrinol Metab. 2016;11(2):113-148. doi: 10.1586/17446651.2016.1131119

42. Mikhail N. Quick-release bromocriptine for treatment of type 2 diabetes. Curr Drug Deliv. 2011;8(5):511-516. doi: 10.2174/156720111796642294

43. Di Rosa M, Malaguarnera L. Chitinase 3 like-1: An emerging molecule involved in diabetes and diabetic complications. Pathobiology. 2016;83(5):228-242. doi: 10.1159/000444855

44. Lananna BV, McKee CA, King MW, et al. Chi3l1/YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer’s disease pathogenesis. Sci Transl Med. 2020;12(574):eaax3519. doi: 10.1126/scitranslmed.aax3519

45. Miller S, Son YL, Aikawa Y, et al. Isoform-selective regulation of mammalian cryptochromes. Nat Chem Biol. 2020;16(6):676-685. doi: 10.1038/s41589-020-0505-1

46. He B, Nohara K, Park N, et al. The small molecule nobiletin targets the molecular oscillator to enhance circadian rhythms and protect against metabolic syndrome. Cell Metab. 2016;23(4):610-621. doi: 10.1016/j.cmet.2016.03.007

47. McLaughlin TM, Liu T, Yee G, et al. Pioglitazone increases the proportion of small cells in human abdominal subcutaneous adipose tissue. Obesity (Silver Spring). 2010;18(5):926-931. doi: 10.1038/oby.2009.380

48. Ashrafizadeh M, Zarrabi A, Saberifar S, et al. Nobiletin in cancer therapy: How this plant-derived natural compound targets various oncogene and onco-suppressor pathways. Biomedicines. 2020;8(5):110. doi: 10.3390/biomedicines8050110